Approval · Notice of Compliance 21038 · 2018
JAMP REPAGLINIDE: Notice of Compliance 21038
Issued June 28, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21038
- Date
- June 28, 2018
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Change in product ownership
- Canadian reference product
- GLUCONOORM (Novo Nordisk Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP REPAGLINIDE | 02354926 | Marketed |
| JAMP REPAGLINIDE | 02354934 | Marketed |
| JAMP REPAGLINIDE | 02354942 | Marketed |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB